New Approaches to Fight Serious Diseases.
VBL Therapeutics is a clinical stage biotechnology company using its
unique scientific platforms and drug development capabilities to fight
immune inflammatory diseases and cancer. These serious and sometimes life
threatening diseases are inadequately addressed by current therapies. VBL
Therapeutics is committed to developing novel treatments that address
this unmet need.
Novel Technology, Promising Therapies.
VBL Therapeutics pioneered the Lecinoxoid class of oral anti-inflammatory agents. Our lead Lecinoxoid, VB-201, is currently in a Phase 2 clinical development for the treatment of psoriasis, atherosclerosis, IBD, and other anti-inflammatory disorders. In addition, VBL Therapeutics developed an innovative, proprietary platform technology for gene therapy in blood vessels designated VTS™ (Vascular Targeting System). We have used this technology to develop promising therapeutic compounds for cancer and ischemic diseases. VB-111, our lead oncology drug candidate, is in Phase 2 clinical development in five cancer indications.
Making an Impact for Patients in the Clinic.
Our first-in-class compound, VB-201 has completed Phase 2 clinical proof-of-concept studies for the treatment of psoriasis and inflammation in atherosclerosis. VB-201 is currently in Phase 2b study in psoriasis and an exploratory Phase 2 in ulcerative colitis. VBL Therapeutics has entered Phase 2 clinical development with VB-111, the company’s lead oncology drug candidate, in thyroid cancer, glioblastoma multiforme, renal cell cancer, neuroendocrine tumors and ovarian cancer.
Find out more about our:
Phase 2 Psoriasis clinical trial